BRCA2 and neoplasm: In addition, the inherently high baseline genomic instability in BRCA2-mutant tumor lines may render them intrinsically hypersensitive to HU and cisplatin, limiting the extent of rescue achievable by siRNA-mediated A3B depletion alone.